Janssen Ends Collaboration with Geron to Develop Cancer Candidate Imetelstat

Johnson & Johnson’s (J&J) Janssen Biotech has ended a nearly four-year-old collaboration with Geron, which as a result is regaining rights to the blood cancer candidate imetelstat, the companies said today—but is seeing its stock lose two-thirds of its value this morning.Janssen said in a terse statement that its decision “is the result of a strategic portfolio evaluation and prioritization of assets” within its portfolio.The companies inked an up-to-$935 million